 BeiGene Ltd NASDAQ: BGNE has announced results from the Phase 3 ALPINE trial of Brukinsa zanubrutinib in relapsed or refractory RR chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. Brukinsa demonstrated superiority versus Johnson Johnsons. 